Compile Data Set for Download or QSAR
maximum 50k data
Report error Found 90 Enz. Inhib. hit(s) with all data for assayid = 1 entry...
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM120095(US10525036, Example GDC-0994 | US10934304, Example...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM120095(US10525036, Example GDC-0994 | US10934304, Example...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM50094465(CHEMBL3590106 | US10525036, Example BVD-523 | US10...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM50094465(CHEMBL3590106 | US10525036, Example BVD-523 | US10...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM50094464(CHEMBL3590107 | US10525036, Example SCH772984 | US...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM50094464(CHEMBL3590107 | US10525036, Example SCH772984 | US...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421838(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421838(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phenyl)...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846((R)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM426336((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM426336((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421849((5S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)ph...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421849((5S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)ph...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421851((S)-7-(2-(4-(4-(1H-1,2,3-Triazol-1-yl)phenyl)-3,6-...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421851((S)-7-(2-(4-(4-(1H-1,2,3-Triazol-1-yl)phenyl)-3,6-...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421852((S)-2-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421852((S)-2-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421853((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421853((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421854((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421854((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421855((S)-7-(2-(4-(4-(5-(Ethylamino)-1,3,4-oxadiazol-2-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421855((S)-7-(2-(4-(4-(5-(Ethylamino)-1,3,4-oxadiazol-2-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421856((S)-7-(2-(4-(4-(5-(Ethylamino)-1,3,4-thiadiazol-2-...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421856((S)-7-(2-(4-(4-(5-(Ethylamino)-1,3,4-thiadiazol-2-...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421857((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421857((S)-7-(2-(4-(4-(1-Methyl-1H-1,2,4-triazol-3-yl)phe...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421859((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421859((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421860((S)-7-(2-(4-(4-(5-Fluoropyrimidin-2-yl)phenyl)-3,6...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421860((S)-7-(2-(4-(4-(5-Fluoropyrimidin-2-yl)phenyl)-3,6...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421861((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421863((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421865((S)-7-(2-(4-(4-(5-Fluoropyrimidin-2-yl)phenyl)-3,6...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421865((S)-7-(2-(4-(4-(5-Fluoropyrimidin-2-yl)phenyl)-3,6...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421866((S)-2-(3-(4-Fluorophenyl)-1H-indazol-5-yl)-7-(2-(4...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421866((S)-2-(3-(4-Fluorophenyl)-1H-indazol-5-yl)-7-(2-(4...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421867((S)-2-(3-(2-Isopropoxypyridin-4-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421867((S)-2-(3-(2-Isopropoxypyridin-4-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 3(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421868((S)-2-(3-(3-Fluoropyridin-4-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421868((S)-2-(3-(3-Fluoropyridin-4-yl)-1H-indazol-5-yl)-7...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMitogen-activated protein kinase 1(Homo sapiens (Human))
Recurium Ip Holdings

US Patent
LigandPNGBDBM421869((S)-2-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-y...)
Affinity DataIC50: <50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: